Terms: = Prostate cancer AND EIF3E, eIF3-p46, 3646, ENSG00000104408, EIF3S6, eIF3e, EIF3-P48, INT6 AND Treatment
4 results:
1. [Drug discovery by formulation design and innovative drug delivery systems (DDS)].
Okada H
Yakugaku Zasshi; 2011; 131(9):1271-87. PubMed ID: 21881300
[TBL] [Abstract] [Full Text] [Related]
2. Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System.
Félix J; Andreozzi V; Soares M; Borrego P; Gervásio H; Moreira A; Costa L; Marcelo F; Peralta F; Furtado I; Pina F; Albuquerque C; Santos A; Passos-Coelho JL;
Value Health; 2011 Jun; 14(4):499-505. PubMed ID: 21669375
[TBL] [Abstract] [Full Text] [Related]
3. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract] [Full Text] [Related]
4. Prostatic specific antigen as an indicator of response to radiotherapy in prostate cancer.
Landmann C; Hunig R
Int J Radiat Oncol Biol Phys; 1989 Nov; 17(5):1073-6. PubMed ID: 2478510
[TBL] [Abstract] [Full Text] [Related]
